Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

ASX Announcements

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Jul 31, 2023
Quarterly Activities/Appendix 4C Cash Flow Report
Jul 19, 2023
Notification regarding unquoted securities - KZA
Jul 17, 2023
Change in substantial holding
Jul 14, 2023
Proposed issue of securities - KZA
Jul 14, 2023
Appendix 2A
Jul 14, 2023
Cleansing Notice
Jul 13, 2023
Notification of cessation of securities - KZA
Jul 11, 2023
Change in substantial holding
Jul 7, 2023
Paxalisib receives Fast Track Designation from US FDA
Jun 26, 2023
Kazia Corporate Update and Corporate Presentation
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 19
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement